David P. Meeker - Feb 1, 2024 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
President and CEO, Director
Signature
/s/ Hunter Smith, Attorney-in-Fact for David Meeker
Stock symbol
RYTM
Transactions as of
Feb 1, 2024
Transactions value $
-$196,507
Form type
4
Date filed
2/5/2024, 06:53 PM
Previous filing
Jun 30, 2023
Next filing
Feb 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise +14.1K +12.69% 125K Feb 1, 2024 Direct F1
transaction RYTM Common Stock Sale -$197K -4.36K -3.48% $45.06 121K Feb 1, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Options Exercise $0 -14.1K -25% $0.00 42.4K Feb 1, 2024 Common Stock 14.1K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3 The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.